Referências

1. Consultas, Bulário Eletrônico. ANVISA, 2022. Detalhe da Bula do Produto: Kesimpta. Disponível em: https://consultas.anvisa.gov.br/#/bulario/detalhe/1415215?nomeProduto=KESIMPTA. Acesso em 10 fev. 2022. 2. Kobelt, Gisela, et al. "Burden and cost of multiple sclerosis in Brazil." PLoS One 14.1 (2019): e0208837 3. Ziemssen T, Derfuss T, de Stefano N, et al. “Optimizing treatment success in multiple sclerosis”. J Neurol. 2016;263(6):1053-1065. 4. Filippi, M., Danesi, R., Derfuss, T. et al. “Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis”. J Neurol 269, 1670–1677 (2022). 5. Harding K, Williams O, Willis M, et al. “Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis”. JAMA Neurol. 2019;76(5):536–541. 6. Gärtner, Jutta, et al. "Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II." Multiple Sclerosis Journal (2022): 13524585221078825. proaches in relapsing multiple sclerosis.” Lancet Neurol. 2019;18(10):973-980. 7. Hauser, Stephen L., et al. "Ofatumumab Versus Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from the ASCLEPIOS I and II Trials." International Journal of MS Care 22 (2020). 8. Hauser, Stephen L., et al. "Ofatumumab versus teriflunomide in multiple sclerosis." New England Journal of Medicine 383.6 (2020): 546-557. 9. Lu, G., et al. "The evolution of “No Evidence of Disease Activity” in multiple sclerosis." Multiple sclerosis and related disorders 20 (2018): 231-238.

---